A new milestone has been reached for ALB-Trial!
The FLASH ALB-Trial team has now visited participating hospitals around Europe prior to the start of the study!
The next big step towards the start of the Albumin study (ALB-TRIAL) has now been taken. The ALB-TRIAL team at FLASH has spent the past two weeks on initiation visits to hospitals in Germany, the Netherlands, Belgium, and Spain. All the hospitals will participate in the study by recruiting patients from the respective countries and ensuring that the study includes a total of 240 patients with cirrhosis and fluid in the abdominal cavity. The visits have consisted of a review of practical information, a tour of the departments, experience sharing and clarification of the last questions and practical tasks before ALB-TRIAL really starts.
Brief about the study: ALB-TRIAL is a new international study which is part of the MICROB-PREDICT EU Horizon2020 consortium. The aim is to investigate whether a new blood test can be used to predict which patients with cirrhosis and fluid in the abdominal cavity will benefit most from regular human albumin infusions.
You can read much more about the study on our website by following the link below:
https://www.sdu.dk/da/forskning/flash/flash_studier/albumin_studiet
